| 0 (0%) | 11-30 07:31 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 279.49 | 1-year : | 326.44 |
| Resists | First : | 239.28 | Second : | 279.49 |
| Pivot price | 229.6  |
|||
| Supports | First : | 222.23 | Second : | 211.69 |
| MAs | MA(5) : | 230.58 |
MA(20) : | 226.28 |
| MA(100) : | 214.9 |
MA(250) : | 198.79 |
|
| MACD | MACD : | 1.4 |
Signal : | 1.6 |
| %K %D | K(14,3) : | 57.5 |
D(3) : | 64.8 |
| RSI | RSI(14): 49.6 |
|||
| 52-week | High : | 244.8 | Low : | 164.38 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ABBV ] has closed above bottom band by 40.5%. Bollinger Bands are 14% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 233.02 - 234.17 | 234.17 - 235.1 |
| Low: | 223.47 - 225.03 | 225.03 - 226.29 |
| Close: | 225.49 - 227.84 | 227.84 - 229.74 |
Sat, 29 Nov 2025
Assessing AbbVie’s (ABBV) Valuation: Is There More Upside After Recent Performance? - Yahoo Finance
Sat, 29 Nov 2025
Canadian Approval of SKYRIZI in Ulcerative Colitis Might Change the Case for Investing in AbbVie (ABBV) - simplywall.st
Fri, 28 Nov 2025
ABBV - Abbvie Inc Stock Price and Quote - Finviz
Wed, 26 Nov 2025
Is AbbVie Stock Outperforming the Nasdaq? - Markets Financial Content
Wed, 26 Nov 2025
AbbVie (ABBV) Valuation in Focus After Landmark FDA Approval for EPKINLY Combination Therapy - simplywall.st
Fri, 14 Nov 2025
AbbVie (ABBV): Evaluating Valuation Following Strong Results, Dividend Hike, and Key Strategic Shifts - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 1,770 (M) |
| Shares Float | 1,760 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 75 (%) |
| Shares Short | 18,890 (K) |
| Shares Short P.Month | 16,290 (K) |
| EPS | 1.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.5 |
| Profit Margin | 4 % |
| Operating Margin | 35.5 % |
| Return on Assets (ttm) | 9.5 % |
| Return on Equity (ttm) | 137.9 % |
| Qtrly Rev. Growth | 9.1 % |
| Gross Profit (p.s.) | 24.07 |
| Sales Per Share | 33.69 |
| EBITDA (p.s.) | 16.67 |
| Qtrly Earnings Growth | -88.7 % |
| Operating Cash Flow | 20,860 (M) |
| Levered Free Cash Flow | 20,800 (M) |
| PE Ratio | 172.49 |
| PEG Ratio | 0 |
| Price to Book value | -151.81 |
| Price to Sales | 6.75 |
| Price to Cash Flow | 19.32 |
| Dividend | 1.63 |
| Forward Dividend | 0 |
| Dividend Yield | 0.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|